Cancer begins in your cells, which are the building blocks of your body. Normally, your body forms new cells as you need them, replacing old cells that die. Sometimes this process goes wrong. New cells grow even when you don't need them, and old cells don't die when they should. These extra cells can form a mass called a tumor. Tumors can be benign or malignant. Benign tumors aren't cancer while malignant ones are. Cells from malignant tumors can invade nearby tissues. They can also break away and spread to other parts of the body.
More than 18 percent of U.S. adults do not know whether they will have enough to eat from day to day, and the numbers are worse for Hispanics, Blacks, people with obesity, and women, a new report shows.
New data presented at ESMO 2020 have shown that immunotherapy is beneficial for patients with gastric and esophageal cancers who currently have poor survival. (1-3)
Pollution particles, including metals, have been found in the placentas of fifteen women in London, according to research led by Queen Mary University of London.
Patients with BRCA1/2 mutations are at higher risk for breast, ovarian and prostate cancers that can be aggressive when they develop - and, in many cases, resistant to lifesaving drugs.
An immunotherapy agent combined with a tyrosine kinase inhibitor drug significantly improved progression-free survival and reduced the risk of death compared to a single agent treatment in advanced kidney cancer patients, according to first results of a phase 3 clinical trial. The pivotal study could lead to a new treatment option for patients with metastatic kidney cancer.
A recent study published in the journal Nature Medicine, led by researchers James Riley, PhD, a professor of Microbiology at the Perelman School of Medicine at the University of Pennsylvania, and Todd Allen, PhD, a professor of Medicine at Harvard Medical School and Group Leader at the Ragon Institute of MGH, MIT and Harvard, describes a new Dual CAR T cell immunotherapy that can help fight HIV infection
Cancer driver genes have modifications that are crucial for the development and proliferation of tumor.
Capecitabine is a chemotherapy drug used for breast and colorectal Cancer cancer. It can extend survival rate by nearly 10%.
Dr. O'Keefe speaks to AZoLifeSciences about his latest research that investigated how the pesco-mediterranean diet may lower the risk for heart disease.
According to a new study, the removal of a single gene makes poxviruses—a lethal family of viral infections that spread from animals to humans—harmless.
Scientists have detected a second path to treat chronic myelogenous leukemia, which is known to affect older adults, despite its resistance to drugs.
Researchers at the University of Bern have discovered a mechanism in the body’s own immune system which is responsible for the maturation and activation of immune cells.
Interpreting the particular mutations that play a role in different forms of cancer is crucial to enhance diagnosis and treatment.
A Rutgers-led team has created a smart drug delivery system that reduces inflammation in damaged nervous tissues and may help treat spinal cord injuries and other neurological disorders.
The most rudimentary activity of a living thing is to change one copy of its genome into two copies, creating one cell into two.
Scientists have gained a deeper insight into the complexity of the surrounding in which T cells flourish.
The stem cells tasked with creating and maintaining biological tissues have a difficult job. They have to precisely divide to form new specialized cells, which are destined to different fates even though they contain identical DNA. An obvious question then is: How do the cells divide in all the right ways to produce a healthy tissue?
Professor James Kadonaga speaks to AZoLifeSciences about his research into gene activation, and how artificial intelligence can help to aid its discovery.
Research led by Dr. Wonmuk Hwang has led to a better understanding of how components of the body's immune system find intruding or damaged cells, which could lead to novel approaches to viral and cancer treatments.
Researchers at Queen Mary University of London, The Institute of Cancer Research, London, and the Moffitt Cancer Centre have created a mathematical model that can determine the impact of the immune system on tumor evolution.